Dr. Yom is a radiation oncologist who specializes in the treatment of head and neck and lung cancers. She received her M.D. from the University of Pennsylvania in 2002 and completed her residency training at the prestigious M.D. Anderson Cancer Center in Houston, Texas. In 2007, she joined the UCSF faculty as an Assistant Professor of Clinical Radiation Oncology.
Dr. Yom is particularly interested in emerging radiotherapeutic and biologic techniques aimed at reducing the toxicities of treatment. In head and neck cancer, she has studied a variety of issues related to chemoradiation and combined modality treatments, technical aspects of radiation delivery, and radiation-related prognostic factors and post-treatment management. Specifically in lung cancer, she has been involved in efforts to quantify the risks of pneumonitis and esophagitis resulting from concurrent treatment with chemotherapy and radiation and helped to establish intensity-modulated radiation therapy in the treatment of locoregionally advanced lung cancers.
Evidencing her commitment to patient care and patient-oriented research, Dr. Yom has been the recipient of numerous awards including the ASTRO Fellowship from the Korean American Society for Therapeutic Radiology & Oncology, the Jesse H. Jones Fellowship in Cancer Education for excellence in cancer education at M.D. Anderson Cancer Center, an award from the A. Lavoy Moore Endowment Fund for excellence in lung cancer research, and the Eleanor Montague Distinguished Resident Award in Radiation Oncology from the American Association of Women Radiologists. She has authored numerous peer-reviewed articles and is a regularly invited speaker to fellow professionals in the field.
In lung cancer, Dr. Yom has conducted research quantifying the risks of pneumonitis and esophagitis when chemotherapy and radiation are given simultaneously. Her research findings were important in establishing the early use of intensity-modulated radiation therapy for lung cancer in combination with 4-dimensional CT-based planning. She has particular expertise in the delivery of chemoradiation therapy for advanced-stage lung cancer, and also the delivery of non-invasive stereotactic CyberKnife radiation for early-stage lung cancer. Her hope is that better understanding of radiation toxicities will permit higher treatment doses, increase the rate of cure and improve patient quality of life. She is strongly committed to research that will lead to more effective, less toxic, and more highly individualized therapy for patients.
Dr. Yom is an investigator on many research studies in head and neck and lung cancer at UCSF, including trials related to to image-guided radiation, head and neck patients' quality of life, and combinations of novel systemic agents with radiation therapy. She is especially interested in improved clinical and translational prognostic models in order to provide more effective and individualized therapy. It is hoped that the reduction of toxicities, both through technical and biologic means, will improve patients' quality of life and potentially enable physicians to deliver more intelligently targeted radiation and chemotherapy doses in search of a better chance of cure. She believes in multidisciplinary management and a unified, team-oriented approach to patient care
Fogh S, Yom SS. Symptom management during the radiation oncology treatment course: a practical guide for the oncology clinician. Semin Oncol. 2014 Dec; 41(6):764-75. View in PubMed
Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Oct; 12(10):1454-87. View in PubMed
Thariat J, Yom SS, Sanguineti G, Corry J. Oncology scan-nodal regions, nodal regression, and molecular biomarkers: new thinking in head and neck radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Nov 1; 90(3):477-9. View in PubMed
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20; 32(27):2940-50. View in PubMed
Okoye CC, Jablons DM, Jahan TM, Kukreja J, Cardozo S, Yom SS. Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavity. Am J Clin Oncol. 2014 Aug; 37(4):350-5. View in PubMed
Yom SS, Cohen E. The ACR appropriateness criteria® for thyroid carcinoma: Searching for consensus in a rapidly evolving area. Oral Oncol. 2014 Jun; 50(6):575-6. View in PubMed
Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Smith RV, Worden F, Yeung AR, Beitler JJ. ACR Appropriateness Criteria® thyroid carcinoma. Oral Oncol. 2014 Jun; 50(6):577-86. View in PubMed
Yom SS. Q&A with dr jay s. Cooper about radiation therapy oncology group 9003. Int J Radiat Oncol Biol Phys. 2014 May 1; 89(1):10-2. View in PubMed
Yu J, Aldabagh B, Wang J, Yom SS, El-Sayed I, Knott D, McGrath MH, Arron S. Multidisciplinary management of advanced Basal cell carcinoma: report of four cases. J Drugs Dermatol. 2014 May 1; 13(5):601-6. View in PubMed
Ouyang D, El-Sayed IH, Yom SS. National trends in surgery for sinonasal malignancy and the effect of hospital volume on short-term outcomes. Laryngoscope. 2014 Jul; 124(7):1609-14. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.